At CES Unveiled the announcement of 50 selected participants of the Dutch CES2020 Trade Mission* was honored by the participation of His Royal Highness Constantijn van Oranje-Nassau, Special Envoy StartupDelta. The ‘Consumer Electronics Show’ CES2020 will enable Plasmacure to show its device for stimulating the healing of chronic wounds and meet potential investors, collaboration partners and distribution partners that can introduce the product to the US market.
Dutch medtech start-up company Plasmacure has developed a device that stimulates the healing of chronic wounds. Chronic wounds affect 140 million people worldwide. Every 30 seconds someone on the planet loses a foot due to amputation, more than 80% caused by diabetic foot ulcers. This is horrible and has a high impact on quality of life.
The global costs of wound care are also huge: $200 Billion a year. The US has the highest number of people suffering from diabetic foot ulcers and the highest financial burden of wound care. Current advanced wound care therapies don’t solve the problem. New solutions are required.
A new treatment for hard-to-heal wounds: cold plasma
Plasmacure brings an innovative solution called PLASOMA to treat hard-to-heal wounds with a cold atmospheric plasma. A cold plasma is created by ionizing a gas by means of a strong electric field. Plasma kills bacteria in less than one minute, even the antibiotic resistant ones. It also stimulates cell proliferation and improves microcirculation. The patented cold plasma solution offers an affordable and safe treatment for hard-to-heal wounds that takes only a few minutes time.
"This trade mission is a great opportunity for us to show the PLASOMA device to the US market. For people with a non-healing wound the quality of life is severely reduced. Plasmacure wants to help those people that have run out of options. Preventing amputations with ground-breaking technology, who wouldn't want to contribute to that?" – said the CEO and founder of the company, Bas Zeper.
First results at Amsterdam UMC are very promising: this study with participation of 20 patients demonstrated that within 2 weeks time over 50% of the wounds responded very well to the treatment and 10% healed completely. The wounds existed for 1090 days on average.**
Initiated by Technical University Eindhoven TU/e, PLASOMA was further developed by Bas Zeper, the CEO and founder of Plasmacure. The Eindhoven based company has steadily grown its highly motivated team and is ready to bring PLASOMA to the market.
Plasmacure is the winner of the prestigious Accenture Innovation Award 2016 in the category Health and Wellbeing sector and Finalist of European Institute of Innovation and Technology (EIT) Health Catapult competition 2018.
*The Dutch CES2020 Trade Mission is powered by The Netherlands Ministry of Foreign Affairs, Netherlands Enterprise Agency (RVO), StartupDelta and partners.
Terug naar het overzicht